It Is Offical , CLVS SEC Filing - Response Rate 28% Much Lower Then Expected. ,,, read
Clovis Oncology, Inc. - Ir
The following excerpt is from the company's SEC filing.
As the efficacy data had matured, the number of patients with an unconfirmed response who converted to a confirmed response was lower than expected. In the intent-to-treat analysis of the 79 patients in the 500 milligrams dose group, the current confirmed response rate is 28% and in the 170 patients in the 625
milligram dose group, its 34%. In both cases we have a duration of response of nine months.
Civil Proceedings Against Short-Seller Andrew Left Move Ahead in Hong Kong
Securities and Futures Commission had alleged Citron’s Left published false information in 2012
By Julie Steinberg
Updated Nov. 2, 2015 5:16 p.m. ETHONG KONG—A Hong Kong tribunal is moving ahead with a civil caseagainst U.S. short-seller Andrew Left, whom Hong Kong securities regulators have accused of publishing false information three years ago.